These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
793 related articles for article (PubMed ID: 33708343)
1. Targeting mesenchymal stem cell therapy for severe pneumonia patients. Lam G; Zhou Y; Wang JX; Tsui YP World J Stem Cells; 2021 Feb; 13(2):139-154. PubMed ID: 33708343 [TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Yadav P; Vats R; Bano A; Bhardwaj R Life Sci; 2020 Dec; 263():118588. PubMed ID: 33049279 [TBL] [Abstract][Full Text] [Related]
3. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19. Cai Q; Yin F; Hao L; Jiang W Stem Cells Dev; 2021 May; 30(9):459-472. PubMed ID: 33715385 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320 [TBL] [Abstract][Full Text] [Related]
5. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019. Zayed M; Iohara K Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527 [TBL] [Abstract][Full Text] [Related]
6. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Atluri S; Manchikanti L; Hirsch JA Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286 [TBL] [Abstract][Full Text] [Related]
7. Current Clinical Application of Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients: Review. Adugna DG Stem Cells Cloning; 2021; 14():71-80. PubMed ID: 34785907 [TBL] [Abstract][Full Text] [Related]
8. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Zumla A; Wang FS; Ippolito G; Petrosillo N; Agrati C; Azhar EI; Chang C; El-Kafrawy SA; Osman M; Zitvogel L; Galle PR; Locatelli F; Gorman E; Cordon-Cardo C; O'Kane C; McAuley D; Maeurer M Int J Infect Dis; 2020 Jul; 96():431-439. PubMed ID: 32425638 [TBL] [Abstract][Full Text] [Related]
9. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Golchin A; Seyedjafari E; Ardeshirylajimi A Stem Cell Rev Rep; 2020 Jun; 16(3):427-433. PubMed ID: 32281052 [TBL] [Abstract][Full Text] [Related]
10. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449 [TBL] [Abstract][Full Text] [Related]
11. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Yen BL; Yen ML; Wang LT; Liu KJ; Sytwu HK Stem Cells Transl Med; 2020 Oct; 9(10):1163-1173. PubMed ID: 32526079 [TBL] [Abstract][Full Text] [Related]
12. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19. Klimczak A World J Stem Cells; 2020 Sep; 12(9):1013-1022. PubMed ID: 33033561 [TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects. Abdelgawad M; Bakry NS; Farghali AA; Abdel-Latif A; Lotfy A Stem Cell Res Ther; 2021 Aug; 12(1):469. PubMed ID: 34419143 [TBL] [Abstract][Full Text] [Related]
14. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges]. Wang J; Zou W; Liu J Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1970-1978. PubMed ID: 33169563 [TBL] [Abstract][Full Text] [Related]